Bank of New York Mellon’s Accelerate Diagnostics AXDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-1,438
| Closed | -$11.6K | – | 4345 |
|
|
2023
Q2 | $11.6K | Hold |
1,438
| – | – | ﹤0.01% | 4330 |
|
|
2023
Q1 | $10.1K | Hold |
1,438
| – | – | ﹤0.01% | 4358 |
|
|
2022
Q4 | $10.2K | Hold |
1,438
| – | – | ﹤0.01% | 4421 |
|
|
2022
Q3 | $22K | Sell |
1,438
-1,841
| -56% | -$30.5K | ﹤0.01% | 4440 |
|
|
2022
Q2 | $33K | Sell |
3,279
-7,618
| -70% | -$67.3K | ﹤0.01% | 4433 |
|
|
2022
Q1 | $156K | Buy |
10,897
+637
| +6% | +$18.1K | ﹤0.01% | 4312 |
|
|
2021
Q4 | $536K | Sell |
10,260
-371
| -3% | -$20.7K | ﹤0.01% | 3767 |
|
|
2021
Q3 | $619K | Buy |
10,631
+315
| +3% | +$20.5K | ﹤0.01% | 3678 |
|
|
2021
Q2 | $831K | Sell |
10,316
-1,668
| -14% | -$133K | ﹤0.01% | 3528 |
|
|
2021
Q1 | $997K | Sell |
11,984
-2
| -0% | -$203 | ﹤0.01% | 3332 |
|
|
2020
Q4 | $909K | Sell |
11,986
-1,157
| -9% | -$104K | ﹤0.01% | 3308 |
|
|
2020
Q3 | $1.4M | Sell |
13,143
-89
| -0.7% | -$12.4K | ﹤0.01% | 2902 |
|
|
2020
Q2 | $2.01M | Buy |
13,232
+1,156
| +10% | +$114K | ﹤0.01% | 2670 |
|
|
2020
Q1 | $1M | Buy |
12,076
+165
| +1% | +$23.2K | ﹤0.01% | 2975 |
|
|
2019
Q4 | $2.01M | Buy |
11,911
+522
| +5% | +$86.2K | ﹤0.01% | 2816 |
|
|
2019
Q3 | $2.12M | Sell |
11,389
-134
| -1% | -$25.9K | ﹤0.01% | 2731 |
|
|
2019
Q2 | $2.64M | Sell |
11,523
-557
| -5% | -$109K | ﹤0.01% | 2655 |
|
|
2019
Q1 | $2.54M | Buy |
12,080
+37
| +0.3% | +$6.94K | ﹤0.01% | 2661 |
|
|
2018
Q4 | $1.39M | Sell |
12,043
-70
| -0.6% | -$10.4K | ﹤0.01% | 2920 |
|
|
2018
Q3 | $2.78M | Sell |
12,113
-342
| -3% | -$75.6K | ﹤0.01% | 2680 |
|
|
2018
Q2 | $2.78M | Sell |
12,455
-599
| -5% | -$134K | ﹤0.01% | 2672 |
|
|
2018
Q1 | $2.98M | Buy |
13,054
+214
| +2% | +$56.2K | ﹤0.01% | 2605 |
|
|
2017
Q4 | $3.36M | Buy |
12,840
+154
| +1% | +$36.1K | ﹤0.01% | 2553 |
|
|
2017
Q3 | $2.85M | Sell |
12,686
-2,992
| -19% | -$735K | ﹤0.01% | 2618 |
|
|
2017
Q2 | $4.29M | Buy |
15,678
+3,804
| +32% | +$1.03M | ﹤0.01% | 2402 |
|
|
2017
Q1 | $2.87M | Sell |
11,874
-25
| -0.2% | -$5.71K | ﹤0.01% | 2625 |
|
|
2016
Q4 | $2.47M | Buy |
11,899
+533
| +5% | +$127K | ﹤0.01% | 2726 |
|
|
2016
Q3 | $3.1M | Sell |
11,366
-1,336
| -11% | -$296K | ﹤0.01% | 2497 |
|
|
2016
Q2 | $1.83M | Sell |
12,702
-131
| -1% | -$17.6K | ﹤0.01% | 2767 |
|
|
2016
Q1 | $1.84M | Buy |
12,833
+484
| +4% | +$68.3K | ﹤0.01% | 2703 |
|
|
2015
Q4 | $2.65M | Buy |
12,349
+1,434
| +13% | +$262K | ﹤0.01% | 2549 |
|
|
2015
Q3 | $1.77M | Sell |
10,915
-3,672
| -25% | -$795K | ﹤0.01% | 2812 |
|
|
2015
Q2 | $3.77M | Buy |
14,587
+2,212
| +18% | +$528K | ﹤0.01% | 2540 |
|
|
2015
Q1 | $2.79M | Sell |
12,375
-69
| -0.6% | -$14.4K | ﹤0.01% | 2642 |
|
|
2014
Q4 | $2.39M | Buy |
12,444
+82
| +0.7% | +$17.6K | ﹤0.01% | 2751 |
|
|
2014
Q3 | $2.65M | Buy |
12,362
+520
| +4% | +$101K | ﹤0.01% | 2681 |
|
|
2014
Q2 | $3.08M | Buy |
11,842
+3,734
| +46% | +$815K | ﹤0.01% | 2633 |
|
|
2014
Q1 | $1.77M | Buy |
8,108
+1,659
| +26% | +$246K | ﹤0.01% | 2949 |
|
|
2013
Q4 | $787K | Buy |
6,449
+1,012
| +19% | +$135K | ﹤0.01% | 3416 |
|
|
2013
Q3 | $729K | Buy |
5,437
+309
| +6% | +$27.6K | ﹤0.01% | 3400 |
|
|
2013
Q2 | $416K | Buy |
+5,128
| New | +$381K | ﹤0.01% | 3563 |
|
Other funds holding AXDX
GAM
BC
OIM
CC
CI
TWA
Bank of New York Mellon's AXDX Position: Q3 2023 in Review
Bank of New York Mellon sold out of Accelerate Diagnostics (AXDX) in Q3 2023, closing a stake of 1,438 shares — an estimated $11.6K sold.
Bank of New York Mellon first reported a position in AXDX in Q2 2013 and held it in 41 quarters. The position peaked at $4.29M in Q2 2017. 38 funds tracked by Wall St. Rank hold AXDX as of Q3 2023.
- Bank of New York Mellon reported no remaining Accelerate Diagnostics position as of Q3 2023 after selling out during the quarter.
- Bank of New York Mellon sold 1,438 Accelerate Diagnostics shares in Q3 2023, an estimated $11.6K.
- Bank of New York Mellon first reported a position in Accelerate Diagnostics in Q2 2013 and held it in 41 quarters.
- Bank of New York Mellon's Accelerate Diagnostics position peaked at $4.29M in Q2 2017.
- 38 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2023.
Based on Bank of New York Mellon's 13F filing for Q3 2023, filed 24 Oct 2023.